David Hwang is a pathologist at UHN and an Associate Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto. He completed MD and PhD degrees at the University of Toronto, followed by residency training in Anatomical Pathology. Complementing his clinical practice in pulmonary pathology, his primary research focus is in pulmonary infectious disease. He is currently funded by the National Sanitarium Association to study bacterial community-wide gene expression and its role in antibiotic responses and resistance in the cystic fibrosis lung. He is a member of CIHR Emerging Teams investigating nanotechnology-enabled diagnosis and treatment (led by Dr. Gang Zheng, UHN) and engaged in metagenomic profiling of the cystic fibrosis lung (led by Dr. David Guttman, University of Toronto). In addition to research in pulmonary infections, Dr. Hwang is also involved in lung transplantation and repair research in collaboration with investigators of the Latner Thoracic Research Laboratories and with investigators from the Toronto Lung Transplant Program.
Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.
Mod Pathol. 2019 Sep 04;:
Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation.
J Heart Lung Transplant. 2019 Jul 26;:
Sleep Breath. 2019 Aug 11;:
The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation.
Am J Transplant. 2019 Aug 09;:
Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
Cancer. 2019 Aug 07;:
A B Cell-Dependent Pathway Drives Chronic Lung Allograft Rejection After Ischemia-Reperfusion Injury in Mice.
Am J Transplant. 2019 Jul 31;:
Histogram-based models on non-thin section chest CT predict invasiveness of primary lung adenocarcinoma subsolid nodules.
Sci Rep. 2019 Apr 12;9(1):6009
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Clin Lung Cancer. 2018 Dec 19;:
Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.
NPJ Biofilms Microbiomes. 2019;5:4
Penicillin binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Int J Antimicrob Agents. 2019 Jan 18;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Affiliate Scientist, Toronto General Hospital Research Institute (TGHRI)
Associate Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto